<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115934</url>
  </required_header>
  <id_info>
    <org_study_id>194</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <secondary_id>U01HL068269</secondary_id>
    <secondary_id>U01HL068279</secondary_id>
    <secondary_id>U01HL068281</secondary_id>
    <secondary_id>U01HL068285</secondary_id>
    <secondary_id>U01HL068288</secondary_id>
    <secondary_id>U01HL068290</secondary_id>
    <secondary_id>U01HL068292</secondary_id>
    <nct_id>NCT00115934</nct_id>
  </id_info>
  <brief_title>Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network</brief_title>
  <official_title>Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Heart Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy and safety of the modified Blalock-Taussig shunt (MBTS)
      compared to the right ventricle to pulmonary artery (RV-to-PA) shunt; compare the effect of
      the MBTS to that of the RV-to-PA shunt on the incidence of death or cardiac transplantation
      at 12 months post randomization; and compare the effect of the two shunts on intensive care
      unit (ICU) morbidity, unintended cardiovascular interventional procedures, right ventricular
      function, tricuspid valve regurgitation, pulmonary artery growth, and neurodevelopmental
      outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Hypoplastic left heart syndrome (HLHS) and related single right ventricle anomalies are the
      highest risk congenital cardiovascular malformations. Surgical repair begins with the Norwood
      procedure during the newborn period, a stage II procedure at 4 to 6 months of age, and Fontan
      procedure at 18 to 36 months. The Norwood procedure remains one of the highest risk
      procedures in congenital heart surgery. A few small nonrandomized studies of a novel approach
      to the Norwood procedure have reported improved outcomes. This new approach uses a RV-to-PA
      shunt to provide pulmonary blood flow rather than the standard MBTS. This multi-center,
      randomized clinical trial will evaluate early and intermediate-term outcomes for patients
      undergoing a Norwood procedure with either the RV-to-PA shunt or the MBTS.

      This study has been approved by the Institutional Review/Research Ethics Boards of all
      participating clinical centers:

      Hospital for Sick Children, Toronto, Canada

      Children's Hospital Boston, Boston, MA

      Columbia College of Physicians and Surgeons, New York, NY

      Children's Hospital of Philadelphia, Philadelphia, PA

      Duke University Medical Center, Durham, NC

      Brody School of Medicine at East Carolina University, Greenville, NC

      Wake Forest Baptist Medical Center, Winston Salem, NC

      Medical University of South Carolina, Charleston, SC

      Children's Hospital of Wisconsin, Milwaukee, WI

      University of Michigan, Ann Arbor, MI

      Cincinnati Children's Hospital Medical Center, Cincinnati, OH

      Children's Hospital of Los Angeles, Los Angeles, CA

      Egleston Children's Hospital, Emory University, Atlanta, GA

      Congenital Heart Institute of Florida, University of South Florida, St. Petersburg, FL

      Alfred I. duPont Hospital for Children, Wilmington, DE

      DESIGN NARRATIVE:

      This is a prospective, randomized clinical trial of the RV-to-PA shunt versus MBTS in
      patients undergoing a Norwood procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Died or Received a Heart Transplant</measure>
    <time_frame>Measured at 12 months</time_frame>
    <description>The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial</measure>
    <time_frame>From Randomization to the End of the Trial, an average of 32 months</time_frame>
    <description>This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)</measure>
    <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
    <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</measure>
    <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
    <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</measure>
    <time_frame>Measured at 14 months of age</time_frame>
    <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</measure>
    <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
    <description>Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</measure>
    <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
    <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</measure>
    <time_frame>Measured at 14 months of age</time_frame>
    <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</measure>
    <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
    <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</measure>
    <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
    <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</measure>
    <time_frame>Measured at 14 months of age</time_frame>
    <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Findings: Left Pulmonary Artery Size</measure>
    <time_frame>Measured pre-stage II surgery, on average 26 days prior to stage II palliation</time_frame>
    <description>Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Findings: Right Pulmonary Artery Size</measure>
    <time_frame>Measured pre-stage II surgery, on average 26 days prior to stage II palliation</time_frame>
    <description>Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unintended Cardiovascular Interventional Procedures</measure>
    <time_frame>From Randomization to 12 months</time_frame>
    <description>Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications: Total Number Experienced During Norwood Hospitalization</measure>
    <time_frame>Norwood Hospitalization, an average of 36 days</time_frame>
    <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge</measure>
    <time_frame>From Norwood Discharge to Stage II discharge, an average of 4.2 months</time_frame>
    <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age</measure>
    <time_frame>From Stage II Discharge to 14 Months of Age, an average of 8.9 months</time_frame>
    <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">555</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>MBTS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blalock-Taussig pulmonary artery shunt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RVPAS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right ventricular to pulmonary artery shunt</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blalock-Taussig pulmonary artery shunt</intervention_name>
    <description>Performed at stage I palliative surgery for babies born with HLHS</description>
    <arm_group_label>MBTS</arm_group_label>
    <other_name>MBTS procedure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Right ventricular to pulmonary artery shunt</intervention_name>
    <description>Performed at stage I palliative surgery for babies born with HLHS</description>
    <arm_group_label>RVPAS</arm_group_label>
    <other_name>RV to PA or Sano procedure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hypoplastic left heart syndrome or related single, morphologic right
             ventricle anomaly

          -  Planned Norwood procedure

          -  Informed consent of parent(s) or legal guardian

        Exclusion Criteria:

          -  Single, morphologic left ventricle anomaly

          -  Preoperative identification of anatomy rendering either an MBTS or an RV-to-PA shunt
             technically impossible

          -  Any major congenital abnormality (i.e., congenital diaphragmatic hernia,
             tracheoesophageal fistula) or acquired extra-cardiac disorder (e.g., meconium
             aspiration with need for high frequency ventilation, persistent renal failure
             requiring dialysis) that, in the opinion of the investigator, could independently
             affect the likelihood of the subject meeting the primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Miller, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Research Institutes, Watertown, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Surgical Associates</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System/Mott Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ohye RG, Gaynor JW, Ghanayem NS, Goldberg CS, Laussen PC, Frommelt PC, Newburger JW, Pearson GD, Tabbutt S, Wernovsky G, Wruck LM, Atz AM, Colan SD, Jaggers J, McCrindle BW, Prakash A, Puchalski MD, Sleeper LA, Stylianou MP, Mahony L; Pediatric Heart Network Investigators. Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure. J Thorac Cardiovasc Surg. 2008 Oct;136(4):968-75. doi: 10.1016/j.jtcvs.2008.01.013. Epub 2008 May 19.</citation>
    <PMID>18954638</PMID>
  </reference>
  <results_reference>
    <citation>Johnson JN, Ansong AK, Li JS, Xu M, Gorentz J, Hehir DA, del Castillo SL, Lai WW, Uzark K, Pasquali SK. Celiac artery flow pattern in infants with single right ventricle following the Norwood procedure with a modified Blalock-Taussig or right ventricle to pulmonary artery shunt. Pediatr Cardiol. 2011 Apr;32(4):479-86. doi: 10.1007/s00246-011-9906-y. Epub 2011 Feb 18.</citation>
    <PMID>21331516</PMID>
  </results_reference>
  <results_reference>
    <citation>Virzi L, Pemberton V, Ohye RG, Tabbutt S, Lu M, Atz TC, Barnard T, Dunbar-Masterson C, Ghanayem NS, Jacobs JP, Lambert LM, Lewis A, Pike N, Pizarro C, Radojewski E, Teitel D, Xu M, Pearson GD. Reporting adverse events in a surgical trial for complex congenital heart disease: the Pediatric Heart Network experience. J Thorac Cardiovasc Surg. 2011 Sep;142(3):531-7. doi: 10.1016/j.jtcvs.2010.11.052. Epub 2011 Mar 12.</citation>
    <PMID>21397260</PMID>
  </results_reference>
  <results_reference>
    <citation>Atz AM, Travison TG, Williams IA, Pearson GD, Laussen PC, Mahle WT, Cook AL, Kirsh JA, Sklansky M, Khaikin S, Goldberg C, Frommelt M, Krawczeski C, Puchalski MD, Jacobs JP, Baffa JM, Rychik J, Ohye RG; Pediatric Heart Network Investigators. Prenatal diagnosis and risk factors for preoperative death in neonates with single right ventricle and systemic outflow obstruction: screening data from the Pediatric Heart Network Single Ventricle Reconstruction Trial(âˆ—). J Thorac Cardiovasc Surg. 2010 Dec;140(6):1245-50. doi: 10.1016/j.jtcvs.2010.05.022. Epub 2010 Jun 18.</citation>
    <PMID>20561642</PMID>
  </results_reference>
  <results_reference>
    <citation>Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, Laussen PC, Rhodes JF, Lewis AB, Mital S, Ravishankar C, Williams IA, Dunbar-Masterson C, Atz AM, Colan S, Minich LL, Pizarro C, Kanter KR, Jaggers J, Jacobs JP, Krawczeski CD, Pike N, McCrindle BW, Virzi L, Gaynor JW; Pediatric Heart Network Investigators. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010 May 27;362(21):1980-92. doi: 10.1056/NEJMoa0912461.</citation>
    <PMID>20505177</PMID>
  </results_reference>
  <results_reference>
    <citation>Ohye RG, Devaney EJ, Hirsch JC, Bove EL. The modified Blalock-Taussig shunt versus the right ventricle-to-pulmonary artery conduit for the Norwood procedure. Pediatr Cardiol. 2007 Mar-Apr;28(2):122-5. Epub 2007 Feb 16. Review.</citation>
    <PMID>17308942</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2005</study_first_submitted>
  <study_first_submitted_qc>June 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2005</study_first_posted>
  <results_first_submitted>September 14, 2010</results_first_submitted>
  <results_first_submitted_qc>May 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects undergoing a Norwood were randomized to MBTS or RVPAS at 15 North American centers.</recruitment_details>
      <pre_assignment_details>There were no pre-assignment requirements beyond the initial screening criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MBTS</title>
          <description>Blalock-Taussig pulmonary artery shunt</description>
        </group>
        <group group_id="P2">
          <title>RVPAS</title>
          <description>Right ventricular to pulmonary artery shunt</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="279">279 randomized to MBTS, but 3 did not have a Norwood surgery; one was withdrawn-with limited data.</participants>
                <participants group_id="P2" count="276">276 randomized to RVPAS, but 2 did not have a Norwood surgery and were excluded from analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive intervention</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MBTS</title>
          <description>Blalock-Taussig pulmonary artery shunt</description>
        </group>
        <group group_id="B2">
          <title>RVPAS</title>
          <description>Right ventricular to pulmonary artery shunt</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="549"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="4.1"/>
                    <measurement group_id="B2" value="5.0" spread="4.0"/>
                    <measurement group_id="B3" value="5.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Died or Received a Heart Transplant</title>
        <description>The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.</description>
        <time_frame>Measured at 12 months</time_frame>
        <population>555 subjects were enrolled in the study; 5 of these subjects were excluded from analyses because a Norwood procedure was not performed; 1 subject was excluded because the subject withdrew before the 12-month follow-up, 12-month status was unknown. The data were analyzed on an intention to treat basis, subjects were analyzed as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Died or Received a Heart Transplant</title>
          <description>The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.</description>
          <population>555 subjects were enrolled in the study; 5 of these subjects were excluded from analyses because a Norwood procedure was not performed; 1 subject was excluded because the subject withdrew before the 12-month follow-up, 12-month status was unknown. The data were analyzed on an intention to treat basis, subjects were analyzed as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The original sample size of 456 was based on 85% power, with a two-sided, two sample test of proportions (anticipating 28% MBTS subjects with events, 16% RVPAS subjects with events), and an alpha of 0.05. The critical p-value was 0.044 because four interim analyses were performed. The target trial size was increased from 466 to 554 to account for crossovers. The stopping boundary was crossed at the 4th interim look; however, the trial was not halted, because all subjects were enrolled.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.8</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
            <estimate_desc>The risk difference is defined as the percent of subjects with events in the RVPAS group minus the percent of subjects with events in the MBTS group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial</title>
        <description>This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.</description>
        <time_frame>From Randomization to the End of the Trial, an average of 32 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial</title>
          <description>This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)</title>
        <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
        <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or measures were not able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)</title>
          <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or measures were not able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="76.3" upper_limit="108.1"/>
                    <measurement group_id="O2" value="86.5" lower_limit="73.8" upper_limit="104.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</title>
        <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
        <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</title>
          <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" lower_limit="94.1" upper_limit="138.6"/>
                    <measurement group_id="O2" value="105.2" lower_limit="86.8" upper_limit="125.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</title>
        <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured at 14 months of age</time_frame>
        <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA</title>
          <description>Right ventricular end-diastolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="69.4" upper_limit="100.3"/>
                    <measurement group_id="O2" value="88.9" lower_limit="72.6" upper_limit="104.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
        <description>Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
        <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
          <description>Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="40.2" upper_limit="61.9"/>
                    <measurement group_id="O2" value="44.2" lower_limit="36.6" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
        <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
        <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
          <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="49.9" upper_limit="83.0"/>
                    <measurement group_id="O2" value="57.9" lower_limit="44.6" upper_limit="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon rank-sum test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
        <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured at 14 months of age</time_frame>
        <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA</title>
          <description>Right ventricular end-systolic volume indexed to BSA^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>ml/m^2.6</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" lower_limit="38.5" upper_limit="56.6"/>
                    <measurement group_id="O2" value="50.5" lower_limit="39.7" upper_limit="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
        <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured post-Norwood, an average of 17 days post-Norwood</time_frame>
        <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes used to calculate the ejection fraction.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
          <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes used to calculate the ejection fraction.</population>
          <units>Percentage of RV end-diastolic volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="7.6"/>
                    <measurement group_id="O2" value="48.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
        <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured pre-stage II surgery, an average of 15 days pre-stage II surgery</time_frame>
        <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
          <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>Percentage of RV end-diastolic volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="7.9"/>
                    <measurement group_id="O2" value="44.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
        <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
        <time_frame>Measured at 14 months of age</time_frame>
        <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction</title>
          <description>Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.</description>
          <population>184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.</population>
          <units>Percentage of RV end-diastolic volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="7.4"/>
                    <measurement group_id="O2" value="42.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Findings: Left Pulmonary Artery Size</title>
        <description>Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
        <time_frame>Measured pre-stage II surgery, on average 26 days prior to stage II palliation</time_frame>
        <population>These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Findings: Left Pulmonary Artery Size</title>
          <description>Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
          <population>These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.5"/>
                    <measurement group_id="O2" value="5.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Findings: Right Pulmonary Artery Size</title>
        <description>Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
        <time_frame>Measured pre-stage II surgery, on average 26 days prior to stage II palliation</time_frame>
        <population>These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Findings: Right Pulmonary Artery Size</title>
          <description>Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).</description>
          <population>These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.0"/>
                    <measurement group_id="O2" value="5.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unintended Cardiovascular Interventional Procedures</title>
        <description>Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.</description>
        <time_frame>From Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Unintended Cardiovascular Interventional Procedures</title>
          <description>Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.</description>
          <units>procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Poisson regression</method>
            <method_desc>The offset parameter used in the poisson regression was the log of the number of patients in each treatment arm.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications: Total Number Experienced During Norwood Hospitalization</title>
        <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
        <time_frame>Norwood Hospitalization, an average of 36 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Complications: Total Number Experienced During Norwood Hospitalization</title>
          <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850"/>
                    <measurement group_id="O2" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Poisson Regression</method>
            <method_desc>The offset parameter used in this analysis was the log of the number of patients per treatment arm.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge</title>
        <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
        <time_frame>From Norwood Discharge to Stage II discharge, an average of 4.2 months</time_frame>
        <population>These numbers reflect those patients who were discharged from the hospital after the Norwood procedure and were transplant free.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge</title>
          <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
          <population>These numbers reflect those patients who were discharged from the hospital after the Norwood procedure and were transplant free.</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Poisson Regression</method>
            <method_desc>The offset parameter used in this analysis was the log of the number of patients per treatment arm.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age</title>
        <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
        <time_frame>From Stage II Discharge to 14 Months of Age, an average of 8.9 months</time_frame>
        <population>These numbers reflect the number of patients who were discharged from the hospital after the Stage 2 procedure and were transplant-free.</population>
        <group_list>
          <group group_id="O1">
            <title>MBTS</title>
            <description>Blalock-Taussig pulmonary artery shunt</description>
          </group>
          <group group_id="O2">
            <title>RVPAS</title>
            <description>Right ventricular to pulmonary artery shunt</description>
          </group>
        </group_list>
        <measure>
          <title>Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age</title>
          <description>Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.</description>
          <population>These numbers reflect the number of patients who were discharged from the hospital after the Stage 2 procedure and were transplant-free.</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Poisson regression</method>
            <method_desc>The offset parameter used in this analysis was the log of the number of patients per treatment arm.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the time of randomization through study completion. Adverse events through 12 months after randomization are presented.</time_frame>
      <desc>Serious Adverse Events: (a) death; (b)acute shunt failure requiring intervention; (c) cardiac arrest requiring CPR and medications; (d) cardiopulmonary insufficiency requiring ECMO; (e) cardiovascular re-operation (unplanned); (f) necrotizing enterocolitis requiring laparotomy; and (g) any other event considered serious by the study investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>MBTS</title>
          <description>Blalock-Taussig pulmonary artery shunt</description>
        </group>
        <group group_id="E2">
          <title>RVPAS</title>
          <description>Right ventricular to pulmonary artery shunt</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="275"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cardiac general</sub_title>
                <counts group_id="E1" events="111" subjects_affected="97" subjects_at_risk="275"/>
                <counts group_id="E2" events="73" subjects_affected="63" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="275"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/soft tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="275"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/genitourinary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="275"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery/intra-operative injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="275"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>PHN coding dictionar</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="249" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="64" subjects_affected="48" subjects_at_risk="275"/>
                <counts group_id="E2" events="73" subjects_affected="57" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="316" subjects_affected="161" subjects_at_risk="275"/>
                <counts group_id="E2" events="266" subjects_affected="148" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="138" subjects_affected="93" subjects_at_risk="275"/>
                <counts group_id="E2" events="133" subjects_affected="94" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious</sub_title>
                <counts group_id="E1" events="313" subjects_affected="156" subjects_at_risk="275"/>
                <counts group_id="E2" events="401" subjects_affected="172" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="51" subjects_affected="35" subjects_at_risk="275"/>
                <counts group_id="E2" events="77" subjects_affected="53" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="41" subjects_affected="39" subjects_at_risk="275"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="285" subjects_affected="154" subjects_at_risk="275"/>
                <counts group_id="E2" events="387" subjects_affected="172" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="275"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As in all surgical trials comparing two operations, it was not possible to blind the personnel caring for the subjects to the intervention. However, the components of the primary endpoint, death and transplantation, are discrete objective events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lynn Sleeper, ScD</name_or_title>
      <organization>New England Research Institutes</organization>
      <phone>617-972-3235</phone>
      <email>lsleeper@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

